Please select the option that best describes you:
Do you have safety concerns when prescribing GLP-1 medications in patients on corticosteroids or immunosuppressive therapy?
This question is part of our collaboration with ACR Convergence 2025 to preview a session from this year's meeting. This question is inspired by the upcoming session "GLP1 Agonists in Rheumatic Disease and Osteoarthritis: Should We Give Them to Everyone?" by Dr. C. Thomas Appleton and Dr. Francis Berenbaum.
Answer from: at Community Practice
I think we need to be particularly careful when co-prescribing with systemic corticosteroids because of the risk of sarcopenia. We know that rapid weight loss is accompanied not only by a loss of fat tissue but also of muscle. Corticosteroids can also have myotoxicity and cause muscle atrophy. I the...
Sign in or Register to read more